Cepheid Flu Test Wins First CLIA Waiver For PCR Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA granted both a 510(k) clearance and a waiver for point-of-care use to Cepheid’s Xpert Flu +RSV Express test – the first molecular-based, polymerase chain-reaction panel diagnostic to win a CLIA waiver.